Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1109-1114

  Yurimoto, Satoshi ^a   Miyakawa, Akira ^b   Okuzawa, Atsushi ^a   Sakamoto, Shuichi ^a   Sakamoto, Kazuhiro ^a   Hosoda, Seiya ^a   Kamano, Toshiki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b 3 23 4 Ninomiya Tsukuba 305   (Japan)

Author keywords

Cisplatin; Mechanism; Mouse; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; FLUOROURACIL; RNA; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TUMOR LEVEL; ENZYME INHIBITION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CISPLATIN; DRUG COMBINATIONS; FLUOROURACIL; MALE; MICE; MICE, INBRED STRAINS; OXONIC ACID; PYRIDINES; RNA, NEOPLASM; SARCOMA 180; TEGAFUR; THYMIDINE KINASE; URIDINE TRIPHOSPHATE;

EID: 27644586802     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00010     Document Type: Article

References (34)

1. Aroori S, Parshad R, Kapoor A, Gupta SD, Kumar A, Chattophadyay TK. Neoadjuvant chemotherapy in squamous cell carcinoma of the esophagus using low dose continuous infusion 5-fluorouracil and cisplatin: results of a prospective study. Indian J Cancer 2004; 41:3-7.
2. Sekiguchi H, Akiyama S, Fujiwara M, Nakamura H, Kondo K, Kasai Y, et al. Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus. Surg Today 1999; 29:97-101.
3. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23:1891-1897.
4. Tsuji A, Morita S, Horimi T, Takasaki M, Takahashi I, Shirasaka T. Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers [in Japanese]. Jpn J Cancer Chemother 1999; 26:933-938.
5. Enjoji A. Combination chemotherapy of 5-fluorouracil and low-dose cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan. Anticancer Res 2002; 22:1135-1139.
6. Murakami S, Yoshida K, Kin R, Nishimoto N, Kagawa Y, Yano Y, et al. The clinical effect of low-dose FP (5-FU + low-dose CDDP) in patients with far advanced gastric cancer, and their quality of life [in Japanese]. Jpn J Cancer Chemother 2000; 27:853-858.
7. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K, Toge T. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 1999; 5:921-926.
8. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997; 80:1-7.
9. Kondo K, Murase M, Kodera Y, Akiyama S, Ito K, Yokoyama Y, et al. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 1996; 53:64-67.
10. Furuhata T, Hirata K, Yamamitsu S, Kimura H, Sasaki K, Hata F, et al. Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma [in Japanese]. Jpn J Cancer Chemother 1999; 26:1554-1558.
11. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
12. Sato Y, Kondo H, Honda K, Takahari D, Sumiyoshi T, Tsuji Y, et al. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int J Clin Oncol 2005; 10:40-44.
13. Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, et al. Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res 2004; 10:1664-1669.
14. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89:2207-2212.
15. Tsujitani S, Fukuda K, Kaibara N. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer 2003; 6:50-57.
16. Suzuki Y, Ishibiki Y, Kawai K, Sasaki M, Matsuda M, Watanabe T, et al. Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma. Anticancer Drugs 2003; 14:475-479.
17. Kondo K, Akiyama S, Kasai Y, Kato S, Kuno Y, Kataoka M, et al. Antitumor effect of S-1 and cisplatin treatment against human gastric cancer xenografted in nude mice [in Japanese]. Jpn J Cancer Chemother 1997; 24:1103-1108.
18. Kitamura M, Arai K, Iwasaki Y, Takahashi T, Saitoh K, Fujii T, et al. Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis [in Japanese]. Jpn J Cancer Chemother 2000; 27:559-563.
19. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32:167-172.
20. Shirasaka T, Shimamoto Y, Ohshimo H, Kimura A, Fukushima M. Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil [in Japanese]. Jpn J Cancer Chemother 1991; 18:403-409.
21. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83:8923-8925.
22. Fujishima H, Nakano S, Masumoto N, Esaki T, Tatsumoto T, Kondo T, et al. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Oncol Res 1997; 9:167-172.
23. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 1996; 65:479-484.
24. Kamano T, Mikami Y, Shirasaka T. Continuous infusion of 5-fluorouracil plus low-dose cisplatin in tumor-bearing mice. Anticancer Drugs 1997; 8:632-636.
25. Masuike T, Watanabe I, Takemoto Y. Quantitative method of 5-fluorouracil and its metabolites in biological samples using high performance liquid chromatography [in Japanese]. Yakugaku Zasshi 1985; 105:1058-1064.
26. Masuike T, Kikuchi K, Saito A, Hashimoto T, Takemoto Y. Determination of 5-fluorouracil incorporated into RNA in tissue using gas chromatographymass spectrometry [in Japanese]. Antibiotics Chemother 1995; 11:162-167.
27. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984; 44:4144-4150.
28. Tsujinaka T, Kido Y, Shiozaki H, Iijima S, Homma T, Sakaue M, et al. Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. Cancer 1992; 70:2761-2765.
29. Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JL, Allegra CJ. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 1996; 32A:2148-2154.
30. Iba T, Yagi Y, Kidokoro A, Fukunaga M, Momose F, Nagakari K. Intermittent low-dose cisplatin infusion as a possible modulator of 5-fluorouracil. Int J Clin Oncol 1997; 2:197-201.
31. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39:205-211.
32. Chiu CS, Chan AK, Wright JA. Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II). Biochem Cell Biol 1992; 70:1332-1338.
33. Smith SL, Douglas KT. Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin. Biochem Biophys Res Commun 1989; 162:715-723.
34. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, et al. Superior antitumour activity with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 2003; 39:2387-1394.